## **Aniline derivatives**

Publication date: 1998-10-13

Inventor(s):

THOMAS ANDREW PETER (GB); BROWN DEARG SUTHERLAND (GB); MORRIS

JEFFREY JAMES (GB)

Applicant(s)::

ZENECA LTD (GB)

Requested

Patent:

WO9615118

Application

Number:

US19970836362 19970521

Priority Number

(s):

GB19940022866 19941112; GB19950007308 19950407; WO1995GB02606 19951108

**IPC** 

Classification:

A61K31/51; A61K31/535; C07D403/00; C07D239/82

FC

C07D239/94, C07D401/12, C07D403/12, C07D405/12, C07D409/12, C07D413/12,

Classification:

C07D417/12

Equivalents:

AU3813095, AU703328, CA2200871, DE69507505D, DE69507505T, EP0790986

(WO9615118), <u>B1</u>, ES2128092T, FI971970, JP10508616T, NO307178B, NO972152,

NZ294917

## **Abstract**

PCT No. PCT/GB95/02606 Sec. 371 Date May 12, 1997 Sec. 102(e) Date May 12, 1997 PCT Filed Nov. 8, 1995 PCT Pub. No. WO96/15118 PCT Pub. Date May 23, 1996The invention concerns aniline derivatives

(I) wherein m is 1, 2 or 3, n is 0, 1, 2 or 3, Q is phenyl or naphthyl or a 5- or 6-membered of formula I heteroaryl moiety containing 1, 2 or 3 heteroatoms selected from oxygen, nitrogen and sulfur, and X, R1 and R2 are defined in the claims; or pharmaceutical compositions containing them, and the methods of using the compounds as tyrosine kinase inhibitors and for the treatment of proliferative diseases such as cancer.

Data supplied from the esp@cenet database - I2

- Please see exhibit 60-